Clinical, Immunological and Virological Characterization of COVID-19 Patients That Test Re-positive for SARS-CoV-2 by RT-PCR
Overview
Authors
Affiliations
Background: Some COVID-19 cases test positive again for SARS-CoV-2 RNA following negative test results and discharge, raising questions about the meaning of virus detection. Better characterization of re-positive cases is urgently needed.
Methods: Clinical data were obtained through Guangdong's COVID-19 surveillance network. Neutralization antibody titre was determined using microneutralization assays. Potential infectivity of clinical samples was evaluated by cell inoculation. SARS-CoV-2 RNA was detected using three different RT-PCR kits and multiplex PCR with nanopore sequencing.
Findings: Among 619 discharged COVID-19 cases, 87 re-tested as SARS-CoV-2 positive in circumstances of social isolation. All re-positive cases had mild or moderate symptoms at initial diagnosis and were younger on average (median, 28). Re-positive cases (n = 59) exhibited similar neutralization antibodies (NAbs) titre distributions to other COVID-19 cases (n = 218) tested here. No infectious strain could be obtained by culture and no full-length viral genomes could be sequenced from re-positive cases.
Interpretation: Re-positive SARS-CoV-2 cases do not appear to be caused by active reinfection and were identified in ~14% of discharged cases. A robust NAb response and potential virus genome degradation were detected in almost all re-positive cases, suggesting a substantially lower transmission risk, especially through respiratory routes.
Bioinspired designer DNA NanoGripper for virus sensing and potential inhibition.
Zhou L, Xiong Y, Dwivedy A, Zheng M, Cooper L, Shepherd S Sci Robot. 2024; 9(96):eadi2084.
PMID: 39602515 PMC: 11750070. DOI: 10.1126/scirobotics.adi2084.
Martin-Sanchez M, Wu P, Adam D, Yang B, Lim W, Lin Y Public Health Pract (Oxf). 2024; 8:100525.
PMID: 39050010 PMC: 11267049. DOI: 10.1016/j.puhip.2024.100525.
Cao Z, Sun F, Ding H, Tian Z, Cui Y, Yang W Front Public Health. 2024; 12:1377135.
PMID: 38947348 PMC: 11211536. DOI: 10.3389/fpubh.2024.1377135.
El Hajj H, Bish D, Bish E, Aprahamian H Nav Res Logist. 2024; 69(1):3-20.
PMID: 38607835 PMC: 8251476. DOI: 10.1002/nav.21985.
Pathophysiological, immunological, and inflammatory features of long COVID.
Bohmwald K, Diethelm-Varela B, Rodriguez-Guilarte L, Rivera T, Riedel C, Gonzalez P Front Immunol. 2024; 15:1341600.
PMID: 38482000 PMC: 10932978. DOI: 10.3389/fimmu.2024.1341600.